adMare
News

News - Thumbnail

June 17 2024

Zymeworks Announces FDA Clearance Of Investigational New Drug Application For ZW171, A Novel 2+1 T-Cell Targeting Bispecific Antibody For Mesothelin-Expressing Cancers

Read
News - Thumbnail

June 10 2024

Zymeworks Announces China NMPA Acceptance Of Biologics License Application For Zanidatamab For Second-Line Treatment Of Biliary Tract Cancer

Read
News - Thumbnail

June 06 2024

Domain Therapeutics strengthens its intellectual property for its series of Treg depleting anti-CCR8 antibodies, including best-in-class candidate DT-7012

Read
News - Thumbnail

May 23 2024

Abdera Therapeutics Announces FDA Clearance of IND Application for ABD-147

Read
News - Thumbnail

March 19 2024

Flosonics Medical Secures $20 Million USD in Series C Funding Led by New Leaf Venture Partners to Accelerate Growth

Read
News - Thumbnail

March 12 2024

Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy

Read
News - Thumbnail

March 04 2024

Find Therapeutics Announces Appointment of Dr. Anthony Johnson to its Board of Directors

Read
News - Thumbnail

February 27 2024

Domain Therapeutics promotes Stephan Schann as Chief Scientific Officer (CSO)

Read
News - Thumbnail

November 08 2023

Thryv Therapeutics Presents Benefits of Therapeutic SGK1 Inhibition with THRV-1268 in a Murine Model of Atrial Fibrillation at American Heart Association Scientific Sessions

Read
News - Thumbnail

October 10 2023

Specific Biologics Announces Additional Investment and Appointment of Experienced Biotechnology Leader Steven Kanner, PhD, to the Board of Directors

Read
News - Thumbnail

September 25 2023

Zucara Therapeutics Doses First Patient in Phase 2a ‘ZONE’ Trial

– ZONE study to evaluate the effect of ZT-01 on preventing nighttime hypoglycemia in people with Type 1 diabetes –

– ZT-01 has the potential to become the first therapeutic to prevent nocturnal hypoglycemia, a condition for which there are currently no available therapies –

Read
News - Thumbnail

August 25 2023

Thryv Therapeutics Announces Positive Results from the WAVE 1 Proof of Concept Study.

Read